Current Anti-Amyloid-β Therapy for Alzheimer’s Disease Treatment: From Clinical Research to Nanomedicine

Lecanemab in early Alzheimer's disease

van Dyck, C. H., Swanson, C. J., Aisen, P., Bateman, R. J., Chen, C., Gee, M., Kanekiyo, M., Li, D., Reyderman, L., Cohen, S., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2212948 · Cited by 5,678 · see citing works

2023 Alzheimer's disease facts and figures

(2023) · Alzheimer's & Dementia · doi:10.1002/alz.13016 · Cited by 3,212 · see citing works

Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here?

Leng, F., & Edison, P. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-020-00435-y · Cited by 3,179 · see citing works

Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse

Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160 · see citing works

The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059 · see citing works

Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease

Mawuenyega, K. G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J. C., Yarasheski, K. E., & Bateman, R. J. (2010) · Science · doi:10.1126/science.1197623 · Cited by 2,078 · see citing works

Microglia in Alzheimer’s disease

Hansen, D. V., Hanson, J. E., & Sheng, M. (2018) · Journal of Cell Biology · doi:10.1083/jcb.201709069 · Cited by 1,935 · cited 1× · see citing works

High-Level Neuronal Expression of Aβ_1–42in Wild-Type Human Amyloid Protein Precursor Transgenic Mice: Synaptotoxicity without Plaque Formation

Mucke, L., Masliah, E., Yu, G.-Q., Mallory, M., Rockenstein, E. M., Tatsuno, G., Hu, K., Kholodenko, D., Johnson-Wood, K., & McConlogue, L. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-11-04050.2000 · Cited by 1,856 · see citing works

Mutation of the β-amyloid precursor protein in familial Alzheimer's disease increases β-protein production

Citron, M., Oltersdorf, T., Haass, C., McConlogue, L., Hung, A. Y., Seubert, P., Vigo-Pelfrey, C., Lieberburg, I., & Selkoe, D. J. (1992) · Nature · doi:10.1038/360672a0 · Cited by 1,757 · see citing works

Donanemab in Early Alzheimer’s Disease

Mintun, M. A., Lo, A. C., Duggan Evans, C., Wessels, A. M., Ardayfio, P. A., Andersen, S. W., Shcherbinin, S., Sparks, J., Sims, J. R., Brys, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2100708 · Cited by 1,728 · see citing works

Clearance systems in the brain—implications for Alzheimer disease

Tarasoff-Conway, J. M., Carare, R. O., Osorio, R. S., Glodzik, L., Butler, T., Fieremans, E., Axel, L., Rusinek, H., Nicholson, C., Zlokovic, B. V., et al. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.119 · Cited by 1,678 · see citing works

The glymphatic pathway in neurological disorders.

Rasmussen, M. K., Mestre, H., & Nedergaard, M. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30318-1 · Cited by 1,560 · see citing works

Functional aspects of meningeal lymphatics in ageing and Alzheimer’s disease

Da Mesquita, S., Louveau, A., Vaccari, A., Smirnov, I., Cornelison, R. C., Kingsmore, K. M., Contarino, C., Onengut-Gumuscu, S., Farber, E., Raper, D., et al. (2018) · Nature · doi:10.1038/s41586-018-0368-8 · Cited by 1,445 · see citing works

Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes

Holcomb, L., Gordon, M. N., McGowan, E., Yu, X., Benkovic, S., Jantzen, P., Wright, K., Saad, I., Mueller, R., Morgan, D., et al. (1998) · Nature Medicine · doi:10.1038/nm0198-097 · Cited by 1,386 · see citing works

Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease

Budd Haeberlein, S., Aisen, P. S., Barkhof, F., Chalkias, S., Chen, T., Cohen, S., Dent, G., Hansson, O., Harrison, K., von Hehn, C., et al. (2022) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2022.30 · Cited by 1,367 · see citing works

Alzheimer’s Disease Risk Genes and Mechanisms of Disease Pathogenesis

Karch, C. M., & Goate, A. M. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.05.006 · Cited by 1,357 · see citing works

Microglial Dysfunction and Defective β-Amyloid Clearance Pathways in Aging Alzheimer's Disease Mice

Hickman, S. E., Allison, E. K., & El Khoury, J. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.0616-08.2008 · Cited by 1,329 · cited 1× · see citing works

Alzheimer’s disease: Clinical trials and drug development

Mangialasche, F., Solomon, A., Winblad, B., Mecocci, P., & Kivipelto, M. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70119-8 · Cited by 1,217 · see citing works

Efficacy of acetylcholinesterase inhibitors in Alzheimer’s disease.

Marucci, G., Buccioni, M., Ben, D. D., Lambertucci, C., Volpini, R., & Amenta, F. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108352 · Cited by 1,147 · see citing works

Tau-targeting therapies for Alzheimer disease

Congdon, E. E., & Sigurdsson, E. M. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0013-z · Cited by 1,113 · see citing works

TREM2 Binds to Apolipoproteins, Including APOE and CLU/APOJ, and Thereby Facilitates Uptake of Amyloid-Beta by Microglia

Yeh, F. L., Wang, Y., Tom, I., Gonzalez, L. C., & Sheng, M. (2016) · Neuron · doi:10.1016/j.neuron.2016.06.015 · Cited by 943 · see citing works

Global estimates on the number of persons across the Alzheimer's disease continuum

Gustavsson, A., Norton, N., Fast, T., Frölich, L., Georges, J., Holzapfel, D., Kirabali, T., Krolak‐Salmon, P., Rossini, P. M., Ferretti, M. T., et al. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.12694 · Cited by 895 · see citing works

Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup

Sperling, R. A., Jack, C. R., Black, S. E., Frosch, M. P., Greenberg, S. M., Hyman, B. T., Scheltens, P., Carrillo, M. C., Thies, W., Bednar, M. M., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.05.2351 · Cited by 857 · see citing works

A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody

Swanson, C. J., Zhang, Y., Dhadda, S., Wang, J., Kaplow, J., Lai, R. Y. K., Lannfelt, L., Bradley, H., Rabe, M., Koyama, A., et al. (2021) · Alzheimer's Research & Therapy · doi:10.1186/s13195-021-00813-8 · Cited by 847 · see citing works

A systemic view of Alzheimer disease — insights from amyloid-β metabolism beyond the brain

Wang, J., Gu, B. J., Masters, C. L., & Wang, Y.-J. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.111 · Cited by 808 · see citing works

Molecular mechanisms of protein aggregation from global fitting of kinetic models

Meisl, G., Kirkegaard, J. B., Arosio, P., Michaels, T. C. T., Vendruscolo, M., Dobson, C. M., Linse, S. S., & Knowles, T. P. J. (2016) · Nature Protocols · doi:10.1038/nprot.2016.010 · Cited by 754 · see citing works

Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms

Andorfer, C., Kress, Y., Espinoza, M., De Silva, R., Tucker, K. L., Barde, Y., Duff, K., & Davies, P. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01879.x · Cited by 722 · see citing works

Circadian control of brain glymphatic and lymphatic fluid flow

Hablitz, L. M., Plá, V., Giannetto, M., Vinitsky, H. S., Stæger, F. F., Metcalfe, T., Nguyen, R., Benrais, A., & Nedergaard, M. (2020) · Nature Communications · doi:10.1038/s41467-020-18115-2 · Cited by 704 · see citing works

The β-Secretase BACE1 in Alzheimer’s Disease

Hampel, H., Vassar, R., De Strooper, B., Hardy, J., Willem, M., Singh, N., Zhou, J., Yan, R., Vanmechelen, E., De Vos, A., et al. (2021) · Biological Psychiatry · doi:10.1016/j.biopsych.2020.02.001 · Cited by 694 · see citing works

Alzheimer’s disease drug development pipeline: 2022

Cummings, J., Lee, G., Nahed, P., Kambar, M. E. Z. N., Zhong, K., Fonseca, J., & Taghva, K. (2022) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12295 · Cited by 665 · see citing works

Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients with Early Alzheimer Disease

Salloway, S., Chalkias, S., Barkhof, F., Burkett, P., Barakos, J., Purcell, D., Suhy, J., Forrestal, F., Tian, Y., Umans, K., et al. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2021.4161 · Cited by 619 · see citing works

Emerging blood–brain-barrier-crossing nanotechnology for brain cancer theranostics

Tang, W., Fan, W., Lau, J., Deng, L., Shen, Z., & Chen, X. S. (2019) · Chemical Society Reviews · doi:10.1039/c8cs00805a · Cited by 606 · see citing works

Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and <i>APOE</i> genotype

Vermunt, L., Sikkes, S. A. M., van den Hout, A., Handels, R., Bos, I., van der Flier, W. M., Kern, S., Ousset, P., Maruff, P., Skoog, I., et al. (2019) · Alzheimer's &amp; Dementia · doi:10.1016/j.jalz.2019.04.001 · Cited by 570 · see citing works

Neuropathology and Pathogenesis of Encephalitis following Amyloid β Immunization in Alzheimer's Disease

Ferrer, I., Boada, M., Guerra, M. L. S., Rey, M. J., & Costa‐Jussà, F. R. (2004) · Brain Pathology · doi:10.1111/j.1750-3639.2004.tb00493.x · Cited by 567 · see citing works

Targeting the β secretase BACE1 for Alzheimer’s disease therapy

Yan, R., & Vassar, R. (2014) · Lancet Neurology · doi:10.1016/s1474-4422(13)70276-x · Cited by 550 · see citing works

A Transgenic Alzheimer Rat with Plaques, Tau Pathology, Behavioral Impairment, Oligomeric Aβ, and Frank Neuronal Loss

Cohen, R. M., Rezai-Zadeh, K. P., Weitz, T. M., Rentsendorj, A., Gate, D., Spivak, I. E., Bholat, Y., Vasilevko, V., Glabe, C. G., Breunig, J. J., et al. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.3672-12.2013 · Cited by 522 · see citing works

Targeting the TLR4 signaling pathway by polyphenols: A novel therapeutic strategy for neuroinflammation

Rahimifard, M., Maqbool, F., Moeini-Nodeh, S., Niaz, K., Abdollahi, M., Braidy, N., Nabavi, S. M., & Nabavi, S. F. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2017.02.004 · Cited by 481 · see citing works

Endothelial LRP1 transports amyloid-β1–42 across the blood-brain barrier

Storck, S. E., Meister, S., Nahrath, J., Meißner, J. N., Schubert, N., Di Spiezio, A., Baches, S., Vandenbroucke, R. E., Bouter, Y., Prikulis, I., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci81108 · Cited by 477 · see citing works

Alzheimer’s disease drug development pipeline: 2023

Cummings, J., Zhou, Y., Lee, G., Zhong, K., Fonseca, J., & Cheng, F. (2023) · Alzheimer's &amp; Dementia: Translational Research &amp; Clinical Interventions · doi:10.1002/trc2.12385 · Cited by 477 · see citing works

Meningeal lymphatics affect microglia responses and anti-Aβ immunotherapy

Da Mesquita, S., Papadopoulos, Z., Dykstra, T., Brase, L., Farias, F. G., Wall, M., Jiang, H., Kodira, C. D., de Lima, K. A., Herz, J., et al. (2021) · Nature · doi:10.1038/s41586-021-03489-0 · Cited by 431 · see citing works

Astrocyte contribution to dysfunction, risk and progression in neurodegenerative disorders

Brandebura, A. N., Paumier, A., Onur, T. S., & Allen, N. J. (2023) · Nature Reviews Neuroscience · doi:10.1038/s41583-022-00641-1 · Cited by 427 · see citing works

Cholesterol and matrisome pathways dysregulated in astrocytes and microglia

TCW, J., Qian, L., Pipalia, N. H., Chao, M. J., Liang, S. A., Shi, Y., Jain, B. R., Bertelsen, S. E., Kapoor, M., Marcora, E., et al. (2022) · Cell · doi:10.1016/j.cell.2022.05.017 · Cited by 411 · see citing works

The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer’s disease patients

Kennedy, M., Stamford, A., Chen, X., Cox, K., Cumming, J., Dockendorf, M., Egan, M. F., Ereshefsky, L., Hodgson, R., Hyde, L., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad9704 · Cited by 391 · see citing works

Early-onset and Robust Cerebral Microvascular Accumulation of Amyloid β-Protein in Transgenic Mice Expressing Low Levels of a Vasculotropic Dutch/Iowa Mutant Form of Amyloid β-Protein Precursor

Davis, J., Xu, F., Deane, R., Romanov, G., Previti, M. L., Zeigler, K., Zlokovic, B. V., & Van Nostrand, W. E. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m312946200 · Cited by 373 · see citing works

Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β

Arndt, J. W., Qian, F., Smith, B. A., Quan, C., Kilambi, K. P., Bush, M. W., Walz, T., Pepinsky, R. B., Bussière, T., Hamann, S., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-24501-0 · Cited by 364 · see citing works

Transcriptional signature in microglia associated with Aβ plaque phagocytosis

Grubman, A., Choo, X. Y., Chew, G., Ouyang, J. F., Sun, G., Croft, N. P., Rossello, F. J., Simmons, R., Buckberry, S., Landin, D. V., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23111-1 · Cited by 357 · see citing works

Astrocytic interleukin-3 programs microglia and limits Alzheimer’s disease

McAlpine, C. S., Park, J., Griciuc, A., Kim, E., Choi, S. H., Iwamoto, Y., Kiss, M. G., Christie, K. A., Vinegoni, C., Poller, W. C., et al. (2021) · Nature · doi:10.1038/s41586-021-03734-6 · Cited by 322 · see citing works

Astrocyte reactivity influences amyloid-β effects on tau pathology in preclinical Alzheimer’s disease

Bellaver, B., Povala, G., Ferreira, P. C. L., Ferrari-Souza, J. P., Leffa, D. T., Lussier, F. Z., Benedet, A. L., Ashton, N. J., Triana-Baltzer, G., Kolb, H. C., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02380-x · Cited by 319 · see citing works

Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study

Winblad, B. G., Andreasen, N., Minthon, L., Floesser, A., Imbert, G., Dumortier, T., Maguire, R. P., Blennow, K., Lundmark, J., Staufenbiel, M., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70140-0 · Cited by 311 · see citing works

BACE1 inhibitors: Current status and future directions in treating Alzheimer's disease

Moussa‐Pacha, N. M., Abdin, S. M., Omar, H. A., Alniss, H. Y., & Al‐Tel, T. H. (2019) · Medicinal Research Reviews · doi:10.1002/med.21622 · Cited by 308 · see citing works

Blood-brain barrier–penetrating siRNA nanomedicine for Alzheimer’s disease therapy

Zhou, Y., Zhu, F., Liu, Y., Zheng, M., Wang, Y., Zhang, D., Anraku, Y., Zou, Y., Li, J., Wu, H., et al. (2020) · Science Advances · doi:10.1126/sciadv.abc7031 · Cited by 304 · see citing works

Alzheimer's disease‐associated TREM2 variants exhibit either decreased or increased ligand‐dependent activation

Song, W., Hooli, B., Mullin, K., Jin, S. C., Cella, M., Ulland, T. K., Wang, Y., Tanzi, R. E., & Colonna, M. (2017) · Alzheimer's &amp; Dementia · doi:10.1016/j.jalz.2016.07.004 · Cited by 297 · see citing works

Aducanumab: First Approval

Dhillon, S. (2021) · Drugs · doi:10.1007/s40265-021-01569-z · Cited by 293 · see citing works

Down syndrome and Alzheimer's disease: common pathways, common goals

Hartley, D., Blumenthal, T., Carrillo, M., DiPaolo, G., Esralew, L., Gardiner, K., Granholm, A.-C., Iqbal, K., Krams, M., Lemere, C., et al. (2015) · Alzheimer's &amp; Dementia · doi:10.1016/j.jalz.2014.10.007 · Cited by 290 · see citing works

Sodium rutin ameliorates Alzheimer’s disease–like pathology by enhancing microglial amyloid-β clearance

Pan, R., Ma, J., Kong, X.-X., Wang, X., Li, S., Qi, X., Yan, Y., Cheng, J., Liu, Q., Jin, W., et al. (2019) · Science Advances · doi:10.1126/sciadv.aau6328 · Cited by 290 · see citing works

Safety and tolerability of BAN2401 - a clinical study in Alzheimer’s disease with a protofibril selective Aβ antibody

Logovinsky, V., Satlin, A., Lai, R. Y. K., Swanson, C. J., Kaplow, J. M., Osswald, G., Basun, H., & Lannfelt, L. (2016) · Alzheimer s Research & Therapy · doi:10.1186/s13195-016-0181-2 · Cited by 289 · see citing works

Genetic variations underlying Alzheimer's disease: evidence from genome-wide association studies and beyond

Cuyvers, E., & Sleegers, K. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00127-7 · Cited by 284 · see citing works

Impact of Anti-amyloid-β Monoclonal Antibodies on the Pathology and Clinical Profile of Alzheimer’s Disease: A Focus on Aducanumab and Lecanemab

Shi, M., Chu, F., Zhu, F., & Zhu, J. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.870517 · Cited by 275 · see citing works

The Murine Version of BAN2401 (mAb158) Selectively Reduces Amyloid-β Protofibrils in Brain and Cerebrospinal Fluid of tg-ArcSwe Mice

Tucker, S., Möller, C., Tegerstedt, K., Lord, A., Laudon, H., Sjödahl, J., Söderberg, L., Spens, E., Sahlin, C., Waara, E. R., et al. (2015) · Journal of Alzheimer’s Disease · doi:10.3233/jad-140741 · Cited by 272 · see citing works

Amyloid‐β efflux from the central nervous system into the plasma

Roberts, K. F., Elbert, D. L., Kasten, T. P., Patterson, B. W., Sigurdson, W. C., Connors, R., Ovod, V., Munsell, L. Y., Mawuenyega, K. G., Miller‐Thomas, M. M., et al. (2014) · Annals of Neurology · doi:10.1002/ana.24270 · Cited by 250 · see citing works

Alzheimer's disease-like pathological features in transgenic mice expressing the APP intracellular domain

Ghosal, K., Vogt, D. L., Liang, M., Shen, Y., Lamb, B. T., & Pimplikar, S. W. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0907652106 · Cited by 245 · see citing works

Effects of monoclonal antibodies against amyloid-β on clinical and biomarker outcomes and adverse event risks: A systematic review and meta-analysis of phase III RCTs in Alzheimer’s disease

Avgerinos, K. I., Ferrucci, L., & Kapogiannis, D. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101339 · Cited by 240 · see citing works

Pyroglutamate Amyloid-β (Aβ): A Hatchet Man in Alzheimer Disease

Jawhar, S., Wirths, O., & Bayer, T. A. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.r111.288308 · Cited by 220 · see citing works

Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease

Wessels, A. M., Tariot, P. N., Zimmer, J. A., Selzler, K. J., Bragg, S. M., Andersen, S. W., Landry, J., Krull, J. H., Downing, A. M., Willis, B. A., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.3988 · Cited by 215 · see citing works

Preliminary Results of a Trial of Atabecestat in Preclinical Alzheimer’s Disease

Henley, D., Raghavan, N., Sperling, R., Aisen, P., Raman, R., & Romano, G. (2019) · New England Journal of Medicine · doi:10.1056/nejmc1813435 · Cited by 197 · see citing works

Peripheral clearance of brain-derived Aβ in Alzheimer's disease: pathophysiology and therapeutic perspectives

Cheng, Y., Tian, D., & Wang, Y.-J. (2020) · Translational Neurodegeneration · doi:10.1186/s40035-020-00195-1 · Cited by 195 · see citing works

Self-Protecting Biomimetic Nanozyme for Selective and Synergistic Clearance of Peripheral Amyloid-β in an Alzheimer’s Disease Model

Ma, M., Liu, Z., Gao, N., Pi, Z., Du, X., Ren, J., & Qu, X. (2020) · Journal of the American Chemical Society · doi:10.1021/jacs.0c08395 · Cited by 191 · see citing works

Production of intracellular amyloid‐containing fragments in hippocampal neurons expressing human amyloid precursor protein and protection against amyloidogenesis by subtle amino acid substitutions in the rodent sequence.

Strooper, B. D., Simons, M., Multhaup, G., LEUVEN, F. V., Beyreuther, K. T., & Dotti, C. G. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb00176.x · Cited by 176 · see citing works

Therapeutic potentials of plant iridoids in Alzheimer's and Parkinson's diseases: A review

Dinda, B., Dinda, M., Kulsi, G., Chakraborty, A., & Dinda, S. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.03.009 · Cited by 175 · see citing works

Delivery of the Brainshuttle™ amyloid-beta antibody fusion trontinemab to non-human primate brain and projected efficacious dose regimens in humans

Grimm, H. P., Schumacher, V. L., Schäfer, M. K.-H., Imhof-Jung, S., Freskgård, P., Brady, K., Hofmann, C., Rüger, P., Schlothauer, T., Göpfert, U., et al. (2023) · mAbs · doi:10.1080/19420862.2023.2261509 · Cited by 173 · see citing works

Detection and Management of Amyloid-Related Imaging Abnormalities in Patients with Alzheimer's Disease Treated with Anti-Amyloid Beta Therapy

Barakos, J. A., Purcell, D. D., Suhy, J., Chalkias, S., Burkett, P., Grassi, C. M., Castrillo‐Viguera, C., Rubino, I., & Vijverberg, E. G. B. (2022) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2022.21 · Cited by 170 · see citing works

Nonhuman Primate Models of Alzheimer-Like Cerebral Proteopathy

Heuer, E., F. Rosen, R., Cintron, A., & C. Walker, L. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212799315885 · Cited by 169 · see citing works

Anti-Amyloid Immunotherapies for Alzheimer's Disease: A 2023 Clinical Update

Yadollahikhales, G., & Rojas, J. C. (2023) · Neurotherapeutics · doi:10.1007/s13311-023-01405-0 · Cited by 162 · see citing works

Perivascular space dilation is associated with vascular amyloid-β accumulation in the overlying cortex

Perosa, V., Oltmer, J., Munting, L. P., Freeze, W. M., Auger, C. A., Scherlek, A. A., van der Kouwe, A. J. W., Iglesias, J. E., Atzeni, A., Bacskai, B. J., et al. (2021) · Acta Neuropathologica · doi:10.1007/s00401-021-02393-1 · Cited by 161 · see citing works

Genetics of Alzheimer's Disease

Guerreiro, R. J., & Hardy, J. (2014) · Neurotherapeutics · doi:10.1007/s13311-014-0295-9 · Cited by 158 · see citing works

Amyloid-Related Imaging Abnormalities With Anti-amyloid Antibodies for the Treatment of Dementia Due to Alzheimer's Disease

Withington, C., & Turner, R. S. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.862369 · Cited by 151 · see citing works

UB‐311, a novel UBITh ^® amyloid β peptide vaccine for mild Alzheimer's disease

Wang, C. Y., Wang, P., Chiu, M., Finstad, C. L., Lin, F., Lynn, S., Tai, Y., De Fang, X., Zhao, K., Hung, C., et al. (2017) · Alzheimer's &amp; Dementia: Translational Research &amp; Clinical Interventions · doi:10.1016/j.trci.2017.03.005 · Cited by 150 · see citing works

Glial cells in Alzheimer’s disease: From neuropathological changes to therapeutic implications

Uddin, M. S., & Lim, L. W. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101622 · Cited by 149 · see citing works

Intranasal Delivery of BACE1 siRNA and Rapamycin by Dual Targets Modified Nanoparticles for Alzheimer's Disease Therapy

Yang, X., Yang, W., Xia, X., Lei, T., Yang, Z., Jia, W., Zhou, Y., Cheng, G., & Gao, H. (2022) · Small · doi:10.1002/smll.202203182 · Cited by 135 · see citing works

Pyroglutamate-3 Amyloid-β Deposition in the Brains of Humans, Non-Human Primates, Canines, and Alzheimer Disease–Like Transgenic Mouse Models

Frost, J. L., Le, K. X., Cynis, H., Ekpo, E., Kleinschmidt, M., Palmour, R. M., Ervin, F. R., Snigdha, S., Cotman, C. W., Saido, T. C., et al. (2013) · American Journal Of Pathology · doi:10.1016/j.ajpath.2013.05.005 · Cited by 132 · see citing works

Cerebral cortical development in rodents and primates

Molnár, Z., & Clowry, G. J. (2012) · Progress in brain research · doi:10.1016/b978-0-444-53860-4.00003-9 · Cited by 130 · see citing works

The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer's disease: an EADC-EC viewpoint

Jönsson, L., Wimo, A., Handels, R., Johansson, G., Boada, M., Engelborghs, S., Frölich, L., Jessen, F., Kehoe, P. G., Kramberger, M., et al. (2023) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2023.100657 · Cited by 129 · see citing works

Genetic markers for diagnosis and pathogenesis of Alzheimer's disease

Kim, D., Yeo, S. H., Park, J.-M., Choi, J. Y., Lee, T.-H., Park, S. Y., Ock, M. S., Eo, J., Kim, H., & Cha, H. (2014) · Gene · doi:10.1016/j.gene.2014.05.031 · Cited by 128 · see citing works

Magnetite/Ceria Nanoparticle Assemblies for Extracorporeal Cleansing of Amyloid‐β in Alzheimer's Disease

Kim, D., Kwon, H. J., & Hyeon, T. (2019) · Advanced Materials · doi:10.1002/adma.201807965 · Cited by 122 · see citing works

Donanemab (LY3002813) Phase 1b Study in Alzheimer's Disease: Rapid and Sustained Reduction of Brain Amyloid Measured by Florbetapir F18 Imaging

Lowe, S. L., Evans, C. D., Shcherbinin, S., Cheng, Y.-J., Willis, B. A., Gueorguieva, I., Lo, A., Fleisher, A., Dage, J. L., Ardayfio, P. A., et al. (2021) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2021.56 · Cited by 119 · see citing works

Donanemab (LY3002813) dose‐escalation study in Alzheimer's disease

Lowe, S. L., Willis, B. A., Hawdon, A., Natanegara, F., Chua, L., Foster, J., Shcherbinin, S., Ardayfio, P. A., & Sims, J. R. (2021) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12112 · Cited by 118 · see citing works

Physiological β-amyloid clearance by the liver and its therapeutic potential for Alzheimer’s disease

Cheng, Y., He, C.-Y., Tian, D.-Y., Chen, S.-H., Ren, J.-R., Sun, H.-L., Xu, M.-Y., Tan, C.-R., Fan, D.-Y., Jian, J.-M., et al. (2023) · Acta Neuropathologica · doi:10.1007/s00401-023-02559-z · Cited by 105 · see citing works

Astrocyte–neuron interplay is critical for Alzheimer's disease pathogenesis and is rescued by TRPA1 channel blockade

Paumier, A., Boisseau, S., Jacquier‐Sarlin, M. R., Pernet‐Gallay, K., Buisson, A., & Albrieux, M. (2021) · Brain · doi:10.1093/brain/awab281 · Cited by 104 · see citing works

Pyroglutamate Aβ cascade as drug target in Alzheimer’s disease

Bayer, T. A. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01409-2 · Cited by 98 · see citing works

Accelerating stem cell trials for Alzheimer's disease

Hunsberger, J. G., Rao, M. S., Kurtzberg, J., Bulte, J. W. M., Atala, A., LaFerla, F. M., Greely, H. T., Sawa, A., Gandy, S., Schneider, L. S. S., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00332-4 · Cited by 97 · see citing works

Axonal organization defects in the hippocampus of adult conditional BACE1 knockout mice

Ou-Yang, M.-H., Kurz, J. E., Nomura, T., Popovic, J., Rajapaksha, T. W., Dong, H., Contractor, A., Chetkovich, D. M., Tourtellotte, W. G., & Vassar, R. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aao5620 · Cited by 94 · see citing works

Invited review: Animal models of tauopathies and their implications for research/translation into the clinic

Dujardin, S., Colin, M., & Buée, L. (2014) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12200 · Cited by 88 · see citing works

Cholinergic Neuron Targeting Nanosystem Delivering Hybrid Peptide for Combinatorial Mitochondrial Therapy in Alzheimer’s Disease

Qian, K., Bao, X., Li, Y., Wang, P., Guo, Q., Yang, P., Xu, S., Yu, F., Meng, R., Cheng, Y., et al. (2022) · ACS Nano · doi:10.1021/acsnano.2c05795 · Cited by 87 · see citing works

Efficacy and safety of anti-amyloid-β monoclonal antibodies in current Alzheimer's disease phase III clinical trials: A systematic review and interactive web app-based meta-analysis

Jeremic, D., Navarro‐López, J. D., & Jiménez‐Díaz, L. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102012 · Cited by 82 · see citing works

Murine models of Alzheimer's disease and their use in developing immunotherapies

Wısnıewskı, T., & Sigurdsson, E. M. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2010.05.004 · Cited by 80 · see citing works

Spontaneous formation of β-sheet nano-barrels during the early aggregation of Alzheimer’s amyloid beta

Sun, Y., Käkinen, A., Wan, X., Moriarty, N., Hunt, C. J., Li, Y., Andrikopoulos, N., Nandakumar, A., Davis, T. P., Parish, C. L., et al. (2021) · Nano Today · doi:10.1016/j.nantod.2021.101125 · Cited by 76 · see citing works

Comparison of memory, affective behavior, and neuropathology in APPNLGF knock-in mice to 5xFAD and APP/PS1 mice

Locci, A., Orellana, H., Rodríguez, G., Gottliebson, M., McClarty, B. M., Dominguez, S., Keszycki, R. M., & Dong, H. (2021) · Behavioural Brain Research · doi:10.1016/j.bbr.2021.113192 · Cited by 68 · see citing works

Impacts of FDA approval and Medicare restriction on antiamyloid therapies for Alzheimer's disease: patient outcomes, healthcare costs, and drug development

Brockmann, R., Nixon, J., Love, B. L., & Yunusa, I. U. (2023) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2023.100467 · Cited by 68 · see citing works

Lipoprotein-Inspired Nanoscavenger for the Three-Pronged Modulation of Microglia-Derived Neuroinflammation in Alzheimer’s Disease Therapy

Zhang, H., Jiang, W., Zhao, Y., Song, T., Xi, Y., Han, G., Jin, Y., Song, M., Bai, K., Zhou, J., et al. (2022) · Nano Letters · doi:10.1021/acs.nanolett.2c00191 · Cited by 67 · see citing works

mTOR-Mediated Immunometabolic Reprogramming Nanomodulators Enable Sensitive Switching of Energy Deprivation-Induced Microglial Polarization for Alzheimer’s Disease Management

Yang, F., Zhao, D., Cheng, M., Liu, Y., Chen, Z., Chang, J. K., & Dou, Y. (2023) · ACS Nano · doi:10.1021/acsnano.3c03232 · Cited by 64 · see citing works

Cerebral beta-amyloid angiopathy in aged squirrel monkeys.

Elfenbein, H. A., Rosen, R. F., Stephens, S. L., Switzer, R. C., Smith, Y., Paré, J., Mehta, P. D., Warzok, R., & Walker, L. C. (2007) · PubMed · doi:10.14670/hh-22.155 · Cited by 57 · see citing works

ACU193: An Immunotherapeutic Poised to Test the Amyloid β Oligomer Hypothesis of Alzheimer’s Disease

Krafft, G. A., Jerecı̀ć, J., Siemers, E., & Cline, E. N. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.848215 · Cited by 51 · see citing works

Degradation of Alzheimer’s Amyloid-β by a Catalytically Inactive Insulin-Degrading Enzyme

Sahoo, B. R., Panda, P. K., Liang, W. G., Tang, W., Ahuja, R., & Ramamoorthy, A. (2021) · Journal of Molecular Biology · doi:10.1016/j.jmb.2021.166993 · Cited by 47 · see citing works

Beta-secretase inhibitors in phase I and phase II clinical trials for Alzheimer’s disease

Moussa, C. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1369527 · Cited by 46 · see citing works

Axonal and Schwann Cell BACE1 Is Equally Required for Remyelination of Peripheral Nerves

Hu, X., Hu, J., Dai, L., Trapp, B. D., & Yan, R. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.5207-14.2015 · Cited by 40 · see citing works

Long-term effects of immunotherapy with a brain penetrating Aβ antibody in a mouse model of Alzheimer’s disease

Gustavsson, T., Metzendorf, N. G., Wik, E., Roshanbin, S., Julku, U. H., Chourlia, A., Nilsson, P., Andersson, K. G., Laudon, H., Hultqvist, G., et al. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01236-3 · Cited by 35 · see citing works

Anti-Aβ agents for mild to moderate Alzheimer's disease: systematic review and meta-analysis

Lu, L., Zheng, X., Wang, S., Tang, C., Zhang, Y., Yao, G., Zeng, J., Ge, S., Wen, H., Xu, M., et al. (2020) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2020-323497 · Cited by 35 · see citing works

Cognitive components in mice and humans: Combining genetics and touchscreens for medical translation

Nithianantharajah, J., & Grant, S. G. N. (2013) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2013.06.006 · Cited by 32 · see citing works

Versatile nanomaterials for Alzheimer’s disease: Pathogenesis inspired disease-modifying therapy

Xi, Y., Chen, Y., Jin, Y., Han, G., Song, M., Song, T., Shi, Y., Tao, L., Huang, Z., Zhou, J., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.02.034 · Cited by 27 · see citing works

ACU193, a Monoclonal Antibody that Selectively Binds Soluble Aβ Oligomers: Development Rationale, Phase 1 Trial Design, and Clinical Development Plan

Siemers, E., Hitchcock, J., Sundell, K. L., Dean, R. A., Jerecic, J., Cline, E. N., Iverson, K., Moore, J. A., Edgar, C. J., Manber, R., et al. (2022) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2022.93 · Cited by 25 · see citing works

Charged Tubular Supramolecule Boosting Multivalent Interactions for the Drastic Suppression of Aβ Fibrillation

Ye, Z., Yan, Z.-J., Zhang, C., Hou, J., Yue, S., & Xiao, L. (2021) · Nano Letters · doi:10.1021/acs.nanolett.1c04007 · Cited by 22 · see citing works

Molecular insights into the inhibition of early stages of Aβ peptide aggregation and destabilization of Alzheimer's Aβ protofibril by dipeptide D-Trp-Aib: A molecular modelling approach

Mohammed, A. A., Barale, S. S., Kamble, S. A., Paymal, S. B., & Sonawane, K. D. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.124880 · Cited by 21 · see citing works

Science disconnected: the translational gap between basic science, clinical trials, and patient care in Alzheimer's disease

Gregory, S., Saunders, S., & Ritchie, C. W. (2022) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(22)00219-7 · Cited by 15 · see citing works

A novel transgenic mouse line with hippocampus-dominant and inducible expression of truncated human tau

Gao, Y., Wang, Y., Lei, H., Xu, Z., Li, S., Yu, H., Xie, J., Zhang, Z., Liu, G., Zhang, Y., et al. (2023) · Translational Neurodegeneration · doi:10.1186/s40035-023-00379-5 · Cited by 13 · see citing works

Involvement of astrocyte senescence in Alzheimer's disease

Tüzer, F., & Torres, C. A. (2022) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2022.102594 · Cited by 10 · see citing works

Construction of a small peptide library related to inhibitor OM99-2 and its structure-activity relationship to ?-secretase

Hu, B., Xiong, B., Qiu, B., Li, X., Yu, H., Kun, X. I. A. O., Wang, X., Li, J. X., & Shen, J. (2006) · Acta Pharmacologica Sinica · doi:10.1111/j.1745-7254.2006.00432.x · Cited by 10 · see citing works

Novel Vaccine against Pathological Pyroglutamate-Modified Amyloid Beta for Prevention of Alzheimer’s Disease

Zagorski, K., King, O., Hovakimyan, A., Petrushina, I., Antonyan, T., Chailyan, G., Ghazaryan, M., Hyrc, K. L., Chadarevian, J. P., Davtyan, H., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24129797 · Cited by 8 · see citing works

Meningeal lymphatics in aging and Alzheimer’s disease

Stower, H. (2018) · Nature Medicine · doi:10.1038/s41591-018-0281-6 · Cited by 8 · see citing works

Discovery of potent β-secretase (bace-1) inhibitors by the synthesis of isophthalamide-containing hybrids

Zhu, Y.-P., Xiao, K., Yu, H., Ma, L., Xiong, B., Zhang, H., Wang, X., Li, J.-Y., Li, J. X., & Shen, J. (2009) · Acta Pharmacologica Sinica · doi:10.1038/aps.2008.26 · Cited by 6 · see citing works

Chemical‐Driven Outflow of Dissociated Amyloid Burden from Brain to Blood

Lee, D.-H., Kim, H. V., Kim, H. Y., & Kim, Y. (2022) · Advanced Science · doi:10.1002/advs.202104542 · Cited by 4 · see citing works

Diagnostic criteria for primary progressive mutiple sclerosis: a position paper.

(2000) · Pure Amsterdam UMC · doi:10.1002/1531-8249(200006)47:6 · Cited by 2 · see citing works

Alzheimer’s Disease: Exploring the Landscape of Cognitive Decline

Tenchov, R., Sasso, J. M., & Zhou, Q. A. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00339 · Cited by 170 · see citing works

Amyloid-β induces lipid droplet-mediated microglial dysfunction via the enzyme DGAT2 in Alzheimer’s disease

Prakash, P., Manchanda, P., Paouri, E., Bisht, K., Sharma, K., Rajpoot, J., Wendt, V., Hossain, A., Wijewardhane, P. R., Randolph, C. E., et al. (2025) · Immunity · doi:10.1016/j.immuni.2025.04.029 · Cited by 104 · see citing works

Newer Therapeutic Approaches in Treating Alzheimer’s Disease: A Comprehensive Review

Sree, R. R., Kalyan, M., Anand, N., Mani, S., Gorantla, V. R., Sakharkar, M. K., Song, B., & Chidambaram, S. B. (2025) · ACS Omega · doi:10.1021/acsomega.4c05527 · Cited by 45 · see citing works

Novel Therapeutic Strategies in Alzheimer’s Disease: Pitfalls and Challenges of Anti-Amyloid Therapies and Beyond

Tondo, G., Marchi, F. D., Bonardi, F., Menegon, F., Verrini, G., Aprile, D., Anselmi, M., Mazzini, L., & Comi, C. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13113098 · Cited by 43 · see citing works

Microglial dysfunction in Alzheimer's disease: Mechanisms, emerging therapies, and future directions

Azmal, M., Paul, J. K., Prima, F. S., Haque, A. N. M. S. N. B., Meem, M., & Ghosh, A. (2025) · Experimental Neurology · doi:10.1016/j.expneurol.2025.115374 · Cited by 28 · see citing works

A manifesto for Alzheimer’s disease drug discovery in the era of disease-modifying therapies

Hering, H., Bussière, T., Liu, C., Glajch, K. E., Weihofen, A., Grogan, J. L., & Walsh, D. M. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00872-7 · Cited by 26 · see citing works

Innovative Therapeutic Strategies in Alzheimer’s Disease: A Synergistic Approach to Neurodegenerative Disorders

Niazi, S. K., Magoola, M., & Mariam, Z. (2024) · Pharmaceuticals · doi:10.3390/ph17060741 · Cited by 24 · see citing works

A study to determine the effect of nano-selenium and thymoquinone on the Nrf2 gene expression in Alzheimer’s disease

Ellakwa, D. E., Rashed, L. A., Ali, O. S. M., & El-Sabbagh, N. A. (2025) · Future Science OA · doi:10.1080/20565623.2025.2458434 · Cited by 22 · see citing works

Nrf2/Bach1 signaling axis: A promising multifaceted therapeutic strategy for Alzheimer's disease

Soni, P., Sharma, S. M., Pieper, A. A., Paul, B. D., & Thomas, B. (2025) · Neurotherapeutics · doi:10.1016/j.neurot.2025.e00586 · Cited by 22 · see citing works

Therapeutic Advances in Targeting the Amyloid-β Pathway for Alzheimer’s Disease

Zhang, B., Li, Y., Li, H., Shen, X., & Zhu, Z. (2025) · Brain Sciences · doi:10.3390/brainsci15101101 · Cited by 19 · see citing works

Advancements in Pharmacological Treatment of Alzheimer’s Disease: The Advent of Disease-Modifying Therapies (DMTs)

Wang, Q., Chen, S., Wang, J., Shang, H., & Chen, X. (2024) · Brain Sciences · doi:10.3390/brainsci14100990 · Cited by 17 · see citing works

Amyloid-β Clearance with Monoclonal Antibodies: Transforming Alzheimer’s Treatment

Fatima, R., Khan, Y., Maqbool, M., Ramalingam, P. S., Khan, M. G., Bisht, A. S., & Hussain, M. S. (2025) · Current Protein and Peptide Science · doi:10.2174/0113892037362037250205143911 · Cited by 17 · see citing works

The Role of Non-Coding RNAs in Mitochondrial Dysfunction of Alzheimer’s Disease

Abed, S., Ebrahimi, A., Fattahi, F., Kouchakali, G., Khaniani, M. S., & Derakhshan, S. M. (2024) · Journal of Molecular Neuroscience · doi:10.1007/s12031-024-02262-y · Cited by 16 · see citing works

Unlocking therapeutic potential of siRNA-based drug delivery system for treatment of Alzheimer's disease

Jain, S., Bhushan, B., Mishra, A. K., & Singh, R. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.106413 · Cited by 15 · see citing works

Excess Ub-K48 Induces Neuronal Apoptosis in Alzheimer’s Disease

Li, Q., Yuan, Y., Huang, S., Di, G., Chen, H., Zhuang, Y., Fang, W., Huang, Y., Tao, Y., Jiang, J., et al. (2024) · Journal of Integrative Neuroscience · doi:10.31083/j.jin2312223 · Cited by 12 · see citing works

Albumin antagonizes Alzheimer’s disease-related Tau pathology and enhances cognitive performance by inhibiting aberrant Tau aggregation

Yang, M., Wang, Z., Zhang, Y., Zhang, Z., Li, Y., Wang, R., Su, Q., & Guo, J. (2025) · Experimental Neurology · doi:10.1016/j.expneurol.2025.115155 · Cited by 12 · see citing works

A Soluble Epoxide Hydrolase Inhibitor Improves Cerebrovascular Dysfunction, Neuroinflammation, Amyloid Burden, and Cognitive Impairments in the hAPP/PS1 TgF344-AD Rat Model of Alzheimer’s Disease

Fang, X., Border, J. J., Zhang, H., Challagundla, L., Kaur, J., Hwang, S. H., Hammock, B. D., Fan, F., & Roman, R. J. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26062433 · Cited by 12 · see citing works

Genomic stress and impaired DNA repair in Alzheimer disease

Neven, J., Issayama, L. K., Dewachter, I., & Wilson, D. M. (2024) · DNA repair · doi:10.1016/j.dnarep.2024.103678 · Cited by 11 · see citing works

Tangeretin offers neuroprotection against colchicine-induced memory impairment in Wistar rats by modulating the antioxidant milieu, inflammatory mediators and oxidative stress in the brain tissue

Ogunro, O. B., Karigidi, M. E., Gyebi, G. A., Turkistani, A. A., & Almehmadi, A. H. (2025) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-025-04769-2 · Cited by 10 · see citing works

Multimodal Nano-DESI Mass Spectrometry Imaging Reveals Phospholipids Accumulation in and around Amyloid Plaques in Alzheimer’s Disease

Yang, M., Tang, X., Iqfath, M., Hernly, E., Unsihuay, D., Manchanda, P., Sharma, K. P., Qu, Z., Hu, H., Beveridge, C. H., et al. (2025) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5c00144 · Cited by 10 · see citing works

Integrated machine learning and deep learning-based virtual screening framework identifies novel natural GSK-3β inhibitors for Alzheimer’s disease

Zhou, Y. J., Mu, B., Chen, X., Liu, L., Wu, Q.-L., Lu, M., & Qiao, F.-L. (2025) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-025-00637-w · Cited by 9 · see citing works

Nanomaterials in targeting amyloid-β oligomers: current advances and future directions for Alzheimer's disease diagnosis and therapy

Randhawa, S., Saini, T. C., Bathla, M., Bhardwaj, R., Dhiman, R., & Acharya, A. (2025) · Beilstein Journal of Nanotechnology · doi:10.3762/bjnano.16.44 · Cited by 8 · see citing works

Nano‐Chaperones: Bridging Therapeutics for Amyloid Aggregation in Alzheimer's Disease and Type‐2 Diabetes Mellitus

Siddiqui, F., Mishra, P., Khanam, S., Ranjan, S., Alam, P., Albalawi, T., Khan, S., & Mir, S. S. (2025) · European Journal of Neuroscience · doi:10.1111/ejn.70142 · Cited by 8 · see citing works

The brain-lung axis: Bridging neurological and respiratory disorders via neural-immune-microbial dialogue

Yang, W., Shi, X., Xie, L., Zhang, H., Shen, L., 潘丽, Feng, S., Mao, X., & Wu, X. (2026) · Chinese Journal of Traumatology · doi:10.1016/j.cjtee.2025.10.006 · Cited by 7 · see citing works

Postoperative cognitive dysfunction and neurodegeneration: From inflammation to precision medicine

Lin, X., Yan, L., & Zhu, Q. (2026) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2026.111776 · Cited by 7 · see citing works

Far-Infrared Radiation Ameliorates the Cognitive Dysfunction in an Alzheimer’s Disease Transgenic Mouse via Modulating Jak-2/Stat3 and Nrf-2/HO-1 Pathways

Yang, W., Yu, Q., Wang, N., Lam, K. K. Y., Lin, Z., & Xian, Y. (2025) · NeuroMolecular Medicine · doi:10.1007/s12017-025-08860-2 · Cited by 4 · see citing works

Recent Advances and Future Directions in Alzheimer’s Disease Genetic Research

Stancheva, M., Toncheva, D. I., & Karachanak-Yankova, S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26167819 · Cited by 4 · see citing works

Pathomechanisms, genetic insights, and therapeutics in diabetes-associated dementia

Meher, R., Sahu, R., Ranajit, S. K., Swain, T. R., Acharya, B., Feehan, J., Sahu, P. K., & Apostolopoulos, V. (2025) · Journal of Endocrinology · doi:10.1530/joe-25-0016 · Cited by 4 · see citing works

Alzheimer’s Disease: Evolving Therapeutics, Scientific Progress, and Key Challenges

Sai Yasasvi, K., Goswami, A. K., Prasad, M. R., Chauhan, V. S., & Yadav, N. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02468 · Cited by 4 · see citing works

Construction and Biological Evaluation of Different Nanoshell Thickness Ni@SiO2 Nanotubes as Good Protein Separation Carriers for Bovine Hemoglobin

Cheng, X., Liu, C., Cai, Y., Li, X., Zhao, R., Feng, Y., & Wang, M. (2024) · Current Medicinal Chemistry · doi:10.2174/0109298673307793240802062318 · Cited by 4 · see citing works

NMR Metabolomic Profiling of Differentiated SH-SY5Y Neuronal Cells: Amyloid-β Toxicity and Protective Effects of Galantamine and Lycorine

Kola, A., Costanti, F., Kahfi, J., Emwas, A.-H. M., Jaremko, M., & Valensin, D. (2025) · Cells · doi:10.3390/cells14070525 · Cited by 4 · see citing works

Therapeutic strategies based on macrophages and their derivatives: Targeted drug delivery platforms and disease treatment

Fu, J., Huang, S., Zhang, A., Shi, R., Wei, Y., He, S., Huang, S., Li, L., Sun, X., Gong, T., et al. (2025) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2025.101413 · Cited by 3 · see citing works

Targeted nanomedicine strategies for Alzheimer’s disease therapy

Ardah, M. T., Yaseen, B. M., Malathi, H., Ray, S., Thyagarajan, R., Shankhyan, A., Eshmetov, R., Ataullaev, Z., & Mishra, M. K. (2026) · Discover Nano · doi:10.1186/s11671-026-04763-8 · Cited by 3 · see citing works

Fight Aβ Aggregation with Molecular Aggregates

Wang, C. H., Zhang, D., Hu, M., & Wang, X. (2025) · Macromolecular Chemistry and Physics · doi:10.1002/macp.202400531 · Cited by 2 · see citing works

Nanotechnology and Immunetherapy: reduction of hepatotoxicity and anti-antineoplastic efficiency

Araújo-Filho, I., & do Rêgo, A. C. M. (2024) · JOURNAL OF SURGICAL AND CLINICAL RESEARCH · doi:10.20398/jscr.v15i1.35647 · Cited by 2 · see citing works

From Immune Sanctuary to Neurological Battlefield: The Role of Neuroimmune Cells

Chakrabarti, S. K., & Chattopadhyay, D. (2024) · Exploratory Research and Hypothesis in Medicine · doi:10.14218/erhm.2024.00026 · Cited by 2 · see citing works

G-protein coupled receptor regulates cytoskeletal remodelling of extracellular Tau in Alzheimer’s disease

Chinnathambi, S., Rangappa, N., Velmurugan, G., & Chandrashekar, M. (2025) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2025.10.018 · Cited by 1 · see citing works

Lecanemab and amyloid‐related imaging abnormalities: Real‐world data from a single center experience

Wallace, A., Zhou, O., Hoang, M.-N., Porter, G., Padilla, C., & Marshall, C. D. (2026) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.70377 · Cited by 1 · see citing works

The neuroimmune network in Alzheimer’s and Parkinson’s diseases: from mechanistic insights to biomarker-guided immunotherapies and clinical translation

Fawzy, M. N. (2026) · Inflammopharmacology · doi:10.1007/s10787-026-02363-7 · Cited by 1 · see citing works

Anti-amyloid treatments for Alzheimer's disease: A study on physicians’ perspectives

Shir, D., Shiner, T., & Bregman, N. (2024) · Journal of Alzheimer s Disease · doi:10.1177/13872877241289788 · Cited by 1 · see citing works

Increasing Identification and Follow-Up of Cognitive Impairment in Primary Care: A Quality Improvement Pilot Study

Uomoto, K. E. (2024) · Journal of Primary Care & Community Health · doi:10.1177/21501319241277397

Advancing Alzheimer's Treatment: Unleashing the Power of Donanemab and Quantum Computing for Enhanced Patient Outcomes

Hussain, A., & Hussain, A. (2025) · Current Psychopharmacologye · doi:10.2174/0122115560361749250110074639

Actualización en el diagnóstico y manejo del Alzheimer: revisión narrativa

Luna, D. S. V., Coloma-Ramirez, L., Jácome, P. N. T., Avellán, Á. B. C., Granda-Peñafiel, N., Abril, V. N. C., Palacios, J. A. I., & López, A. D. L. A. C. (2025) · Florence. · doi:10.56183/florence25003

ANTICORPOS ANTI-AMILOIDE NO TRATAMENTO DA DOENÇA DE ALZHEIMER: EFICÁCIA, MECANISMOS E AVANÇOS

Duarte, A. C. G., KLANK, A., FONSECA, B. S., Lima, E. G., Santos, E., Cardoso, L. P. V., Cordeiro, M. H. D. L., ABREU, P. H., Freire, V. N. D. F., & Takahashi, Y. (2025) · Editora Pasteur eBooks · doi:10.59290/978-65-6029-257-4.7

Anti-inflammatory Potential of Dietary Components and Benefits in Alzheimer’s Disease

Lin, G. D., Rodger, A., Malik, J., Smith, P. N., & Li, R. (2025) · Nutritional neurosciences · doi:10.1007/978-981-95-2736-6_3

Targeted isolation and identification of isoquinoline alkaloids from Xylopia ferruginea bark with anti Aβ-induced paralysis activity

Nawi, N. A. M., Hazni, H., Awang, K., Liew, S. Y., Sulaiman, S. N., Salim, F., Bihud, N. V., Nathan, S., Chieng, S., Litaudon, M., et al. (2025) · Fitoterapia · doi:10.1016/j.fitote.2025.107040

Exploring molecular frameworks for modulating NLRP3-driven neuroinflammation in Alzheimer’s disease

Reddy, C. S., Kandy, A. T., Sivakumar, G., & Vijayakumar, A. P. R. (2026) · Molecular Diversity · doi:10.1007/s11030-026-11498-2

From bench to bedside: Emerging therapeutics for alzheimer's disease in clinical trials

Verma, M., & Singh, N. K. (2026) · Metabolic Brain Disease · doi:10.1007/s11011-026-01793-0

Establishing a female rat model of sporadic Alzheimer’s disease via intrahippocampal streptozotocin injection

Zakaria, M. K., Hazalin, N. A. M. N., Chellammal, H. S. J., & Singh, G. K. S. (2026) · Neuroscience and Behavioral Physiology · doi:10.1007/s11055-026-01943-y

Nanodelivery systems for brain-targeted delivery of traditional chinese medicine bioactives in neurodegenerative diseases: Therapeutic mechanisms, translational challenges, and ethical perspectives

Xiong, Y., Liu, H., & Gu, Y. (2026) · Letters in Drug Design & Discovery · doi:10.1016/j.lddd.2026.100441

Apolipoprotein E as a therapeutic target in Alzheimer's disease: A review of basic research and clinical evidence

Kaur, A., Murthy, S., Bharath Kumar, D. R., Gokulakrishnan, S., Philantharopa, U. P. B., & Narajji, C. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-40563-1.00010-7

Cyclic nucleotide signaling through phosphodiesterase 1 inhibition and its interaction with the competing endogenous RNA network regulates cognition

Xu, F., 李海亮, Yan, Y., Chen, L., Sheng, Z., 窦报敏, Chen, Y., Zhu, X., & Xu, Y. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119963

Amyloid-β-targeted therapies for Alzheimer's disease: currently and in the future

Cai, H., Fu, X., Quan, S., Ziye, R., Chu, C., & Longfei, J. (2023) · Ageing and Neurodegenerative Diseases · doi:10.20517/and.2023.16 · Cited by 17 · see citing works

Targeting Amyloid-β Proteins as Potential Alzheimer’s Disease Therapeutics: Anti-Amyloid Drug Discovery, Emerging Therapeutics, Clinical Trials and Implications for Public Health

Abduljawad, A. A., Alkinani, K. B., Zaakan, A., AlGhamdi, A. S., Hamdoon, A. A. E., Alshanbari, B. H., Alshehri, A. A., Alluhaybi, B. B., Alqashi, S. O. I., & Abduljawad, R. A. (2025) · Pharmaceuticals · doi:10.3390/ph18111731 · Cited by 6 · see citing works

Anti-amyloid Monoclonal Antibodies in Alzheimer’s Disease: A New Hope

Nasibova, A. N., Khalilov, R. I., & Eftekhari, A. (2023) · International Journal of Aging · doi:10.34172/ija.2023.e21 · Cited by 1 · see citing works

Amyloid-β Clearance with Monoclonal Antibodies: Transforming Alzheimer’s Treatment

Fatima, R., Khan, Y., Maqbool, M., Ramalingam, P. S., Khan, M. G., Bisht, A. S., & Hussain, M. S. (2025) · Current Protein and Peptide Science · doi:10.2174/0113892037362037250205143911 · Cited by 17 · see citing works

Advancements and Challenges in Antiamyloid Therapy for Alzheimer’s Disease: A Comprehensive Review

Beshir, S. A., Hussain, N., Menon, V. B., Haddad, A. H. I. A., Zeer, R. A. K. A., & Elnour, A. A. (2024) · International Journal of Alzheimer s Disease · doi:10.1155/2024/2052142 · Cited by 22 · see citing works